Speech-Language Pathologists in Memphis, MO Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Trinity Davis Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Rr 2 Box 26, Memphis, MO 63555 Phone: 660-465-7587 |
 Seth Michael Fitzgerald, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 726 N Cecil St, Memphis, MO 63555 Phone: 660-988-7002 |
Kimberly M Mccluskey Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 726 N Cecil St, Memphis, MO 63555 Phone: 660-988-4614 |
Mrs. Ali Gregory, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 438 W Lovers Lane, Memphis, MO 63555 Phone: 660-465-8532 |
News Archive
NIH awards $30 million to accelerate progress in TB vaccine development
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded $30 million in first-year funding to establish new centers for immunology research to accelerate progress in tuberculosis vaccine development.
Nanoparticles activated by X rays used to target deep tumours
A team of researchers from University of Texas at Arlington, University of Rhode Island and Brown University have collaborated to come up with use of nanoparticles in targeted therapy for deep seated cancers. Their success with the nanoparticples was published in a study titled, "X-ray induced photodynamic therapy with copper-cysteamine nanoparticles in mice tumors," was published in the latest issue of the journal Proceedings of the National Academy of Sciences.
Landmark CoMMpass Study data now available through MMRF Researcher Gateway
The Multiple Myeloma Research Foundation announced today that new data from the landmark CoMMpass Study is now available to researchers via the MMRF's Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data publically available for additional study.
Affinium announces AFN-1252 Phase I study results in staphylococcal infections
Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation.
› Verified 1 days ago
Speech-Language Pathologists
Chiropractors
Optometrists
Physical Therapists